文献リスト

1) Moore WE, Holdeman LV. Human fecal flora: the normal flora of 20 Japanese-Hawaiians. Appl Microbiol. 1974; 27: 961-79

2) Finegold SM, Attebery HR, Sutter VL. Effect of diet on human fecal flora: comparison of Japanese and American diets. Am J Clin Nutr. 1974; 27: 1456-69

3) Turroni F, Ribbera A, Foroni E, et al. Human gut microbiota and bifidobacteria: from composition to functionality. Antonie Van Leeuwenhoek. 2008; 94: 35-50

4) Palmer C, Bik EM, Eisen MB, et al. Rapid quantitative profiling of complex microbial populations. Nucleic Acids Res. 2006; 34: e5

5) Matsuda K, Tsuji H, Asahara T, et al. Sensitive quantitative detection of commensal bacteria by rRNA-targeted reverse transcription (RT)-PCR. Appl Environ Microbiol. 2007; 73: 32-9

6) Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science. 2005; 308: 1635-8

7) Matsuki T. Development of quantitative PCR detection method with 16S rRNA gene-targeted genus- and species-specific primers for the analysis of human intestinal microflora and its application. Nippon Saikingaku Zasshi. 2007; 62: 255-61

8) Palmer C, Bik EM, Digiulio DB, et al. Development of the human infant intestinal microbiota. PLoS Biol. 2007; 5: e177

9) Turnbaugh PJ, Ley RE, Hamady M, et al. The human microbiome project. Nature. 2007; 449: 804-10

10) Gill SR, Pop M, Deboy RT, et al. Metagenomic analysis of the human distal gut microbiome. Science. 2006; 312: 1355-9

11) Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006; 444: 1027-31

12) DiBaise JK, Zhang H, Crowell MD, et al. Gut microbiota and its possible relationship with obesity. Mayo Clin Proc. 2008; 83: 460-9

13) Kurokawa K, Itoh T, Kuwahara T, et al. Comparative metagenomics revealed commonly enriched gene sets in human gut microbiomes. DNA Res. 2007; 14: 169-81

14) Scanlan PD, Shanahan F, Clune Y, et al. Culture-independent analysis of the gut microbiota in colorectal cancer and polyposis. Environ Microbiol. 2008; 10: 789-98

15) Ott SJ, Musfeldt M, Wenderoth DF, et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut. 2004; 53: 685-93

16) Eckburg PB, Relman DA. The role of microbes in Crohn's disease. Clin Infect Dis. 2007; 44: 256-62

17) Holton J. Enterotoxigenic Bacteroides fragilis. Curr Infect Dis Rep. 2008; 10: 99-104

18) Sund CJ, Rocha ER, Tzianabos AO, et al. The Bacteroides fragilis transcriptome response to oxygen and H2O2: the role of OxyR and its effect on survival and virulence. Mol Microbiol. 2008; 67: 129-42

19) Penders J, Thijs C, van den Brandt PA, et al. Gut microbiota composition and development of atopic manifestations in infancy: the KOALA Birth Cohort Study. Gut. 2007; 56: 661-7

20) Penders J, Stobberingh EE, van den Brandt PA, et al. Toxigenic and non-toxigenic Clostridium difficile: determinants of intestinal colonisation and role in childhood atopic manifestations. Gut. 2008; 57: 1025-6

21) McFarland LV. Update on the changing epidemiology of Clostridium difficile-associated disease. Nat Clin Pract Gastroenterol Hepatol. 2008; 5: 40-8

22) Nguyen GC, Kaplan GG, Harris ML, et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008; 103: 1443-50

23) Finegold SM. Therapy and epidemiology of autism-clostridial spores as key elements. Med Hypotheses. 2008; 70: 508-11

24) Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008; 134: 577-94

25) Scherberich JE, Hartinger A. Impact of Toll-like receptor signalling on urinary tract infection. Int J Antimicrob Agents. 2008; 31 Suppl 1: S9-14

26) Xuan SY, Xin YN, Chen AJ, et al. Association between the presence of H. pylori in the liver and hepatocellular carcinoma: a meta-analysis. World J Gastroenterol. 2008; 14: 307-12

27) Zhuo XL, Wang Y, Zhuo WL, et al. Possible association of Helicobacter pylori infection with laryngeal cancer risk: An evidence-based meta-analysis. Arch Med Res. 2008; 39: 625-8

28) Turnbaugh PJ, Backhed F, Fulton L, et al. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe. 2008; 3: 213-23

29) Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008; 57: 1470-81

30) Lee S, Son SC, Han MJ, et al. Increased intestinal macromolecular permeability and urine nitrite excretion associated with liver cirrhosis with ascites. World J Gastroenterol. 2008; 14: 3884-90

31) Li S, Wu WC, He CY, et al. Change of intestinal mucosa barrier function in the progress of non-alcoholic steatohepatitis in rats. World J Gastroenterol. 2008; 14: 3254-8

32) Palma P, Mihaljevic N, Hasenberg T, et al. Intestinal barrier dysfunction in developing liver cirrhosis: An in vivo analysis of bacterial translocation. Hepatol Res. 2007; 37: 6-12

33) Erridge C. The roles of pathogen-associated molecular patterns in atherosclerosis. Trends Cardiovasc Med. 2008; 18: 52-6

34) Stecher B, Hardt WD. The role of microbiota in infectious disease. Trends Microbiol. 2008; 16: 107-14

35) Rao VP, Poutahidis T, Fox JG, et al. Breast cancer: should gastrointestinal bacteria be on our radar screen？ Cancer Res. 2007; 67: 847-50

36) Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995; 125: 1401-12

37) van Santvoort HC, Besselink MG, Timmerman HM, et al. Probiotics in surgery. Surgery. 2008; 143: 1-7

38) 金森 豊, 橋都浩平, 諸富正己, 他. 重症小児外科疾患患児の腸内菌叢異常と, probiotics・prebiotics併用療法による腸内細菌叢のコントロール・腸管機能改善効果について. 外科と代謝・栄養. 2000; 34: 49-58

39) 清水健太郎, 小倉裕司, 後藤美紀, 他. SIRS患者における腸内細菌叢, 腸内環境の変化とシンバイオティクス療法の有効性. 日本救急医学会雑誌. 2006; 17: 833-44

40) Kanamori Y, Hashizume K, Kitano Y, et al. Anaerobic dominant flora was reconstructed by synbiotics in an infant with MRSA enteritis. Pediatr Int. 2003; 45: 359-62

41) Kanamori Y, Hashizume K, Sugiyama M, et al. Combination therapy with Bifidobacterium breve, Lactobacillus casei, and galactooligosaccharides dramatically improved the intestinal function in a girl with short bowel syndrome: a novel synbiotics therapy for intestinal failure. Dig Dis Sci. 2001; 46: 2010-6

42) Kanamori Y, Hashizume K, Sugiyama M, et al. A novel synbiotic therapy dramatically improved the intestinal function of a pediatric patient with laryngotracheo-esophageal cleft (LTEC) in the intensive care unit. Clin Nutr. 2002; 21: 527-30

43) Kanamori Y, Sugiyama M, Hashizume K, et al. Experience of long-term synbiotic therapy in seven short bowel patients with refractory enterocolitis. J Pediatr Surg. 2004; 39: 1686-92

44) Nagino M, Kamiya J, Uesaka K, et al. Complications of hepatectomy for hilar cholangiocarcinoma. World J Surg. 2001; 25: 1277-83

45) Berg RD, Garlington AW. Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. Infect Immun. 1979; 23: 403-11

46) Kanazawa H, Nagino M, Kamiya S, et al. Synbiotics reduce postoperative infectious complications: a randomized controlled trial in biliary cancer patients undergoing hepatectomy. Langenbecks Arch Surg. 2005; 390: 104-13

47) Sugawara G, Nagino M, Nishio H, et al. Perioperative synbiotic treatment to prevent postoperative infectious complications in biliary cancer surgery: a randomized controlled trial. Ann Surg. 2006; 244: 706-14

48) Shimizu K, Ogura H, Goto M, et al. Altered gut flora and environment in patients with severe SIRS. J Trauma. 2006; 60: 126-33

49) Shimizu K, Ogura H, Goto M, et al. Synbiotics decrease the incidence of septic complications in patients with severe SIRS: A preliminary report. Dig Dis Sci. 2008; in press

50) Watkinson PJ, Barber VS, Dark P, et al. The use of pre- pro- and synbiotics in adult intensive care unit patients: systematic review. Clin Nutr. 2007; 26: 182-92

51) Besselink MG, van Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 371: 651-9

52) Reid G, Gibson G, Sanders ME, et al. Probiotic prophylaxis in predicted severe acute pancreatitis. Lancet. 2008; 372: 112-3

53) Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007; 448: 427-34

54) Takaishi H, Matsuki T, Nakazawa A, et al. Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. Int J Med Microbiol. 2008; 298: 463-72

55) Ishikawa H, Akedo I, Umesaki Y, et al. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr. 2003; 22: 56-63

56) Kato K, Mizuno S, Umesaki Y, et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther. 2004; 20: 1133-41

57) Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol. 2005; 100: 1539-46

58) Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004; 53: 1617-23

59) Zocco MA, dal Verme LZ, Cremonini F, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 2006; 23: 1567-74

60) Matsuda H, Fujiyama Y, Andoh A, et al. Characterization of antibody responses against rectal mucosa-associated bacterial flora in patients with ulcerative colitis. J Gastroenterol Hepatol. 2000; 15: 61-8

61) Bamba T, Matsuda H, Endo M, et al. The pathogenic role of Bacteroides vulgatus in patients with ulcerative colitis. J Gastroenterol. 1995; 30 Suppl 8: 45-7

62) Imaoka A, Shima T, Kato K, et al. Anti-inflammatory activity of probiotic Bifidobacterium: Enhancement of IL-10 production in peripheral blood mononuclear cells from ulcerative colitis patients and inhibition of IL-8 secretion in HT-29 cells. World J Gastroenterol. 2008; 14: 2511-6

63) Prantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut. 2002; 51: 405-9

64) Schultz M, Timmer A, Herfarth HH, et al. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol. 2004; 4: 5

65) Bousvaros A, Guandalini S, Baldassano RN, et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis. 2005; 11: 833-9

66) Marteau P, Lemann M, Seksik P, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut. 2006; 55: 842-7

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp